Drug intelligence / Profile preview

aflibercept biosimilar (GBS-012)

Development stage: Preclinical
Lead developer: Kidswell Bio
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Ophthalmic

Overview

Aflibercept biosimilar (GBS-012) is a recombinant fusion protein being developed by Kidswell Bio (formerly Gene Techno Science) as a biosimilar to aflibercept for the treatment of ophthalmic diseases, particularly eye disorders. The drug acts as an inhibitor of vascular endothelial growth factor A (VEGF-A) and placental growth factor (PGF), thereby blocking angiogenesis and reducing abnormal blood vessel formation in the eye. It is currently in preclinical development for eye diseases[1][3][4].

Other names: GBS 012GBS012GBS-012

Targets

PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on aflibercept biosimilar (GBS-012).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aflibercept biosimilar (GBS-012).

Explore the full profile